Judgment issued May 11 in Pfizer's lawsuit against "Vaegra" marketer Institute of Sexual Research/David Brady imposes fines totaling $160,000; trademark infringement suit against sham impotence treatment was filed April 20 ("The Tan Sheet" April 27, p. 18). The judgment also prevents ISR, doing business as "American Urological Clinic," from using in any way the Viagra mark "or any colorable imitations thereof, including the VAEGRA name or mark," as well as the drug name sildenafil or "Celldenaphil-pc." Judgment requires Brady to distribute a letter to mailing list retracting previous false "statements, implications or suggestions." Separately, in a case brought by Missouri Attorney General, a Kansas City circuit court orders ISR to refund purchasers of Vaegra. The May 18 order imposes $167,000 in investigative and civil penalties...
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Already a subscriber?
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
A new pilot aims to take Brazil closer to ‘digital transformation.’
Norucholic acid and leriglitazone, for treating primary sclerosing cholangitis and cerebral adrenoleukodystrophy, respectively, are among 12 new drugs that the European Medicines Agency has started to review for potential EU marketing approval.
Although the UK Health Research Authority’s initial proposal for simplified informed consent was rejected by stakeholders, it has yielded valuable insights into reducing trial burden and widening access
Ultragenyx said talks with the FDA about a path forward after receiving a CRL for UX111 have been productive despite the recent upheaval at the agency.
